论文部分内容阅读
研制用于预治新生儿呼吸窘迫综合征（ＲＤＳ）的人工重组肺泡表面活性剂（ＡＰＳ）．方法：采用成膜法结合超声分散制备ＡＰＳ．脉冲气泡表面张力测定法用于评价ＡＰＳ与天然ＰＳ的表面性能．用气管滴注给药临床防治新产儿的ＲＤＳ．结果：制得ＡＰＳ粒径１０μｍ以下的在９９％以上．制剂体外可有效降低表面张力（从４４０ｍＮ／ｍ至１０ｍＮ／ｍ以下）．初步临床试验显示ＡＰＳ能有效预防ＲＤＳ发生（２０／２０）和治疗ＲＤＳ（２／２）．结论：ＡＰＳ制剂体外具有与天然ＰＳ相似的良好表面性能．
Development of artificial recombinant alveolar surfactant (APS) for the treatment of neonatal respiratory distress syndrome (RDS). Methods: APS was prepared by membrane-forming and ultrasonic dispersion. Pulsed bubble surface tension was used to evaluate the surface properties of APS and natural PS. Tracheal instillation for clinical prevention and treatment of newborns RDS. Results: APS particle size of less than 10μm above 99%. Formulation in vitro can effectively reduce the surface tension (from 44 0mN / m to 1 0mN / m below). Preliminary clinical trials have shown that APS can effectively prevent RDS (20/20) and treat RDS (2/2). Conclusion: APS preparation has good surface properties similar to that of natural PS in vitro.